Company news

Keros Therapeutics, Inc. news in 2021

Keros Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

December 12, 2021

Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China

December 12, 2021

Keros Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

November 21, 2021

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

November 14, 2021

Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

November 10, 2021

Keros Therapeutics to Present Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

November 7, 2021

Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

November 3, 2021

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

November 3, 2021

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual Meeting

October 3, 2021

Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences

September 1, 2021

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

August 4, 2021

Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer

August 1, 2021

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

June 21, 2021

Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

June 10, 2021

Keros Therapeutics to Present at the Jefferies Virtual Healthcare Conference

May 26, 2021

Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders

May 24, 2021

Keros Therapeutics Presents Results from Preclinical Study of KER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

May 13, 2021

Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association

May 11, 2021

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

May 5, 2021

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

March 24, 2021

Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference

March 4, 2021

Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference

March 1, 2021

Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

February 16, 2021

Decks in 2021